Brief: Longboard Pharmaceuticals Reports Q2 Results
09/08/2021 15:18
Aug 9 (Reuters) - Longboard Pharmaceuticals Inc LBPH.O :
* LONGBOARD PHARMACEUTICALS - TOPLINE RESULTS OF PHASE 1
CLINICAL
TRIAL FOR LP352 EXPECTED IN 2021
* LONGBOARD PHARMACEUTICALS - PLAN TO INITIATE A PHASE 1B/2A
CLINICAL TRIAL FOR TREATMENT OF DEVELOPMENTAL AND EPILEPTIC
ENCEPHALOPATHIES IN Q1 2022
* LONGBOARD PHARMACEUTICALS - AT JUNE 30, 2021, LONGBOARD'S
CASH,
CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE APPROXIMATELY
$118.8 MILLION
* LONGBOARD PHARMACEUTICALS - NET LOSS WAS $0.41 PER SHARE,
FOR
THREE MONTHS ENDED JUNE 30, 2021
Source text for Eikon: ID:nGNX5ZgMCZ
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions